(Q39545335)

12 September 2017

title

Expression of semenogelins I and II and its prognostic significance in human prostate cancer (English)

1 reference

12 September 2017

1 reference

6

1 reference

12 September 2017

Anastasia M Canacci

1

1 reference

12 September 2017

Koji Izumi

2

1 reference

12 September 2017

Yichun Zheng

3

1 reference

12 September 2017

Jennifer Gordetsky

4

1 reference

12 September 2017

Jorge L Yao

5

1 reference

12 September 2017

publication date

28 December 2010

1 reference

12 September 2017

1 reference

12 September 2017

volume

71

1 reference

12 September 2017

issue

10

1 reference

12 September 2017

page(s)

1108-1114

1 reference

12 September 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Androgen deprivation therapy for prostate cancer: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Biomolecular markers of outcome prediction in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Early versus late hormonal therapy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Human prostate-specific antigen: structural and functional similarity with serine proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Semenogelins I and II bind zinc and regulate the activity of prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Characterization of semenogelin proteins in the human retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Pattern of Gene Expression and Immune Responses to Semenogelin 1 in Chronic Hematologic Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Promotion of bladder cancer development and progression by androgen receptor signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Dietary zinc and prostate cancer in the TRAMP mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Inhibitory effect of zinc on human prostatic carcinoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21323

21 January 2018

Identifiers

DOI

10.1002/PROS.21323

1 reference

12 September 2017

1 reference